Companies › Apellis Pharmaceuticals
3 active drug programs in 6 registered trials: 4 Phase 2, 1 Phase 3, 1 Phase 1; Genitourinary, Hematology, Oncology, Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pegcetacoplan Complement C3 inhibitor | C3 | Phase 3 | C3G; Paroxysmal Nocturnal Hemoglobinuria (PNH); Fallopian Tube Carcinosarcoma; Metastatic Pancreatic Ductal Adenocarcinoma | Jul 2027 |
| APL-3007 Complement C3 inhibitor | C3 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Jun 2027 |
| APL2 Complement C3 inhibitor | C3 | Phase 2 | FSGS | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07215390 | APL-3007 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Ophthalmology | Jun 2027 |
| NCT05809531 | Pegcetacoplan | Phase 3 | C3G | Genitourinary | Jul 2027 |
| NCT07214298 | Pegcetacoplan | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Feb 2028 |
| NCT04919629 | Pegcetacoplan | Phase 2 | Fallopian Tube Carcinosarcoma | Oncology | Apr 2028 |
| NCT04901936 | Pegcetacoplan | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hematology | Dec 2028 |
| NCT07213960 | APL2 | Phase 2 | FSGS | Genitourinary | Oct 2029 |
Annexon Kodiak Sciences Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Shenyang Sunshine Pharmaceutical Swedish Orphan Biovitrum
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Kind Pharmaceuticals Clinique Ovo Sitala Bio Chengdu Suncadia Medicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.